Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:20:26 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ATBPF - ANTIBE THERAPEUTICS INC - https://www.antibethera.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATBPF - Qnot subscribed0.2156    0.8855  0.1113Apr 08Apr 0915 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-09 19:00U:ATBPFNews ReleaseAntibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
2024-04-09 07:00U:ATBPFNews ReleaseAntibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
2024-04-01 07:00U:ATBPFNews ReleaseAntibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
2024-03-20 07:00U:ATBPFNews ReleaseAntibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
2024-03-07 07:00U:ATBPFNews ReleaseAntibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
2024-03-04 07:00U:ATBPFNews ReleaseAntibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
2024-02-14 07:00U:ATBPFNews ReleaseAntibe Reports Q3 2024 Interim Financial and Operating Results
2024-02-01 07:00U:ATBPFNews ReleaseAntibe Extends Early Warrant Exercise Incentive Program
2023-12-29 07:00U:ATBPFNews ReleaseAntibe Announces Early Warrant Exercise Incentive Program
2023-12-12 07:00U:ATBPFNews ReleaseAntibe Therapeutics Announces Amendment to Warrant Terms
2023-11-13 07:00U:ATBPFNews ReleaseAntibe Reports Q2 2024 Interim Financial and Operating Results
2023-11-09 07:00U:ATBPFNews ReleaseAntibe Reports PK Results of First Clinical Study of Otenaproxesul ¢ € ™s New Formulation
2023-11-01 07:00U:ATBPFNews ReleaseAntibe Completes First Clinical Study of Otenaproxesul ¢ € ™s New Formulation
2023-10-18 07:00U:ATBPFNews ReleaseAntibe Initiates First Clinical Study of Otenaproxesul ¢ € ™s New Formulation
2023-09-28 07:00U:ATBPFNews ReleaseAntibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
2023-09-08 17:00U:ATBPFNews ReleaseAntibe Announces Results of 2023 Annual Meeting
2023-08-14 07:00U:ATBPFNews ReleaseAntibe Reports Q1 2024 Interim Financial and Operating Results
2023-06-29 07:30U:ATBPFNews ReleaseAntibe Reports 2023 Year-End Results and Business Highlights
2023-04-25 07:00U:ATBPFNews ReleaseAntibe ¢ € ™s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit